SYRE Spyre Therapeutics, Inc.: institutional ownership and insider trading
278 funds reported holding $8.85B of Spyre Therapeutics, Inc. in their latest 13F filings; in Q2 2026 funds net bought $1.15B, with 87 new positions and 22 funds selling out; over the last 12 months insiders bought $0 and sold $443M on the open market.
Famous investors holding SYRE
- Izzy Englander (Millennium Management): $17.5M, 0.0% of the portfolio
- Ken Griffin (Citadel Advisors): $13.7M, 0.0% of the portfolio
- D. E. Shaw (D. E. Shaw & Co.): $2.35M, 0.0% of the portfolio
- Two Sigma (Two Sigma Investments): $1.13M, 0.0% of the portfolio
Largest institutional holders of SYRE
- FMR LLC — $1.16B
- BlackRock, Inc. (BLK) — $578M
- PERCEPTIVE ADVISORS LLC — $383M
- RTW INVESTMENTS, LP — $377M
- Paradigm Biocapital Advisors LP — $341M
- VANGUARD CAPITAL MANAGEMENT LLC — $306M
- STATE STREET CORP (STT, STT-PG) — $271M
- VR Adviser, LLC — $265M
- PRICE T ROWE ASSOCIATES INC /MD/ — $263M
- DRIEHAUS CAPITAL MANAGEMENT LLC — $249M
Recent SYRE insider trades
- Oct 1, 2026: Burrows Scott L sold 25,000 shares ($2.26M)
- Oct 1, 2026: Turtle Cameron sold 15,000 shares ($1.38M)
- Oct 1, 2026: King-Jones Heidy sold 28,933 shares ($2.63M)
- Sep 2, 2026: Burrows Scott L sold 25,732 shares ($2.28M)
5%+ owners
- Harwin Peter Evan: 10.0% (Schedule 13D/A, filed Oct 9, 2026)
- Peter Evan Harwin: 10.0% (Schedule 13D/A, filed Jun 23, 2026)
- Peter Harwin: 10.0% (Schedule 13D/A, filed Apr 20, 2026)
- Paradigm BioCapital Advisors LP: 5.1% (Schedule 13G, filed Oct 1, 2026)